D.E. Shaw & Co’s Nektar Therapeutics NKTR Stock Holding History

D.E. Shaw & Co’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,167	Closed	-$298K	–	4340
2020 Q4	$298K	Hold	1,167	–	–	﹤0.01%	3603
2020 Q3	$290K	Hold	1,167	–	–	﹤0.01%	3459
2020 Q2	$405K	Hold	1,167	–	–	﹤0.01%	3493
2020 Q1	$312K	Hold	1,167	–	–	﹤0.01%	3450
2019 Q4	$378K	Hold	1,167	–	–	﹤0.01%	3533
2019 Q3	$319K	Buy	+1,167	New	+$428K	﹤0.01%	3430
2019 Q1	–	Sell	-5,000	Closed	-$2.46M	–	3820
2018 Q4	$2.46M	Buy	5,000 +2,587	+107%	+$1.56M	﹤0.01%	1982
2018 Q3	$2.21M	Hold	2,413	–	–	﹤0.01%	2131
2018 Q2	$1.77M	Sell	2,413 -334	-12%	-$385K	﹤0.01%	2325
2018 Q1	$4.38M	Buy	2,747 +1,747	+175%	+$2.25M	0.01%	1497
2017 Q4	$896K	Buy	+1,000	New	+$591K	﹤0.01%	2642

Other funds holding NKTR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's NKTR Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 7,679 shares — an estimated $78.3K sold.

D.E. Shaw & Co first reported a position in NKTR in Q2 2013 and held it in 47 quarters. The position peaked at $77.6M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

D.E. Shaw & Co reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
D.E. Shaw & Co sold 7,679 Nektar Therapeutics shares in Q2 2025, an estimated $78.3K.
D.E. Shaw & Co first reported a position in Nektar Therapeutics in Q2 2013 and held it in 47 quarters.
D.E. Shaw & Co's Nektar Therapeutics position peaked at $77.6M in Q1 2018.
109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.